BioTillion

Executive Summary

BioTillion is a Boston-based biotechnology company that offers RFID-based hardware and software solutions for real-time tracking and management of biological samples in ultra-low temperature (ULT) biobanks. Its technology enables precise localization of sample boxes and vials without removal from cold storage, reducing errors and improving operational efficiency. Core products include the BoxMapper series, ColdSIGHT™ system, and Single Vial Reader. Founded in 2020, the company operates in the AI/Machine Learning and Drug Delivery sectors, targeting a niche but critical need in biorepository management. Despite limited public information on funding or commercial traction, BioTillion's focus on automation and cold-chain integrity positions it well for adoption in pharmaceutical and academic biobanks. The company is private and not yet publicly traded.

Upcoming Catalysts (preview)

• Q4 2026ColdSIGHT™ commercial launch and first customer deployment60% success
• Q2 2027Strategic partnership with a major pharmaceutical or biobank operator45% success
• Q3 2026Series A funding round to scale production and sales50% success